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Abstract
Patient management in Idiopathic Pulmonary Fibrosis (IPF) is largely based on societal guidelines and
recommendations. A recent update by the American Thoracic Society (ATS), European Respiratory Society (ERS),
Japanese Respiratory Society (JRS) and Latin American Thoracic Association (ALAT) provided updated guidance on
the diagnosis and management of IPF, along with recommendations on pharmacologic and non-pharmacologic
approaches to patient management. The treatment guidance is based on GRADE criteria, which rates the quality of
evidence according to previously published methodology. Here we discuss how to interpret the recent guideline
updates and the implications of this guidance for clinical practice. In addition we discuss the assessment and
recommendations for a number of pharmacological agents that have been the focus of clinical trials over the past
years. Although no single pharmacological agent was recommended by the guidelines committee, we discuss how
since then, more recent data have resulted in the approval of pirfenidone in Europe, and preliminary negative
findings regarding the safety of a triple therapy regimen consisting of prednisone, azathioprine and N-
acetylcysteine have raised the question of whether it is no longer a treatment option. As clinicians, we must
interpret the available guidance and recommendations as we consider each individual patient and as we discuss
the available clinical data and the patient’s own preferences in our approach to the management of this disease.
Introduction
The management of patients with Idiopathic Pulmonary
Fibrosis (IPF) is largely based on the recommendations of
prominent societies, such as the American Thoracic
Society (ATS) and the European Respiratory Society
(ERS). The initial recommendations of the ATS/ERS joint
committee were made in 2000; however the guidance pro-
vided stated that at that time there were no existing data
to demonstrate the benefit of any treatment for IPF
patients. [1] Since then, a revised, updated recommenda-
tions document has been published. The 2011 joint
statement of the ATS, ERS, Japanese Respiratory Society
(JRS) and Latin American Thoracic Association (ALAT)
provided further guidance on the diagnosis of IPF and
provided mini-reviews of each of the therapeutic agents
that have been used in studies for the treatment of patients
with IPF. This document also provided detail of the meth-
odological approach to producing these recommendations.
In this paper we discuss the recommendations made by
the committee, data that has since become available
regarding the use of specific drugs, and also suggest the
current implications of these for the IPF physician.
The treatment recommendations and
methodology
The most recent guidelines document provided the over-
all opinion of a voting committee on questions for each
therapeutic agent, for example “should patients with IPF
be treated with corticosteroid monotherapy?”. The section
regarding treatment was structured around these ques-
tions. The committee performed a complete systematic
review of the literature for the questions focused on
treatment. The methodology used for the diagnosis and
treatment sections of the 2011 document followed the
GRADE system. This previously published [2,3] approach
is an evidence-based methodology which rates the quality
of available evidence and strength of recommendations,
following literature searches and assessment of the avail-
able information.
* Correspondence: Juergen.Behr@bergmannsheil.de
1Department of Internal Medicine V, University of Munich, Comprehensive
Pneumology Center, Marchioninistr. 15, 81377 Munich, Germany
Full list of author information is available at the end of the article
Behr and Richeldi Respiratory Research 2013, 14(Suppl 1):S6
http://respiratory-research.com/content/14/S1/S6
© 2013 Behr and Richeldi; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Interpreting the recommendations
The recommendations made based on the GRADE system
are either a ‘strong’ or ‘weak’ recommendation, for or
against a specific treatment. The quality of evidence was
determined using the ATS GRADE criteria, [3] which
identifies all outcomes important to patients and enables
differentiation of critical outcomes from those that are
important but not critical. Recommendations depend on
the available evidence for all patient-important outcomes
and the quality of evidence for each. For each treatment
considered by the committee, the committee graded the
available evidence as either high, moderate, low, or very
low, and then made a recommendation for or against the
treatment being discussed. Recommendations were based
on the majority vote of the committee, and the number of
votes for, against, abstinent, and absent were given for
each ‘strong’ or ‘weak’ recommendation. The strength of a
recommendation reflects the extent to which the treating
physician can be confident that the beneficial effects
outweigh the undesirable effects of a treatment, for the
range of patients for whom the recommendations are
intended [4].
Implications of these recommendations for IPF
clinical practice
While the GRADE recommendations are not widely
understood, in our expert opinion, each recommendation
has three-dimensional implications. The first is for the
patient. If a strong recommendation is made for an IPF
treatment, it is likely that most patients with IPF would
want to follow this course of action, and only a small
number may not. Secondly, and similarly, the implication
for the clinician is that most patients should receive the
intervention if a strong recommendation is made “for” a
specific treatment. The third area of implication is for the
policy makers at a given hospital or institution. If a strong
recommendation for the use of an intervention is made,
this should be adopted as a policy in most situations.
Unfortunately, the key message from the guidelines under
discussion is that no treatments for patients with IPF are
strongly recommended for use (i.e. no treatments received
a “strong y”s’ recommendation). The recommendations
against most therapies are strong, as there is insufficient
evidence supporting their use. However, other treatment
recommendations are weak, reflecting the uncertainty of
the risks and benefits of the data, and the need for higher
quality data. The “weak no” recommendation means that
the majority of patients in this situation would not want
the intervention, but a minority of patients would want it.
In these cases the role of the clinician is of great impor-
tance as they need to help the patient make a treatment
decision regarding a pharmacological agent with a weak
recommendation. Indeed, a weak positive vote should be
interpreted as endorsing the use of a particular therapy,
even if in only a minority of patients. If a patient is well-
informed and strongly wishes to have pharmacological
treatment, this should be selected from the agents with
“weak no” recommendations based on their individual
case. [4] Thus, it could be concluded that the GRADE
system is not ideally suited to such a rare condition that
has no established current best recommended treatment.
Guidance on treatment approaches used in
practice
The recommendation for corticosteroids in patients with
acute exacerbation of IPF is weak; that is, corticosteroids
should be used in the majority of patients with acute
exacerbation of IPF, but not using corticosteroids may be
a reasonable choice in a minority. [4] No randomised,
controlled trials have been performed to investigate their
use in IPF patients, and long-term steroid use is asso-
ciated with significant morbidity. [5]
The guidance focuses on reducing morbidity and the
places a low value on potential improvements in lung
function, due to the low quality of evidence. Treatment
with interferon-gamma-1b was also strongly recom-
mended against. Two randomised, placebo-controlled
trials of interferon-gamma-1b therapy have been con-
ducted in patients with IPF. In the first, published in 2004,
the primary endpoint of improved progression-free survi-
val (PFS) was not met. There was a suggestion of an effect
of interferon-gamma-1b on overall survival, although this
was not significantly greater than that observed with
placebo treatment (p=0.08), and a subgroup analysis sug-
gested an effect on patients with less severe disease at
baseline. [6] However, as this was a small study (n=330),
another larger trial (INSPIRE Study), investigated the
effect on overall survival in a greater number of patients
(n=826). Data from this study showed that interferon-
gamma-1b did not improve survival for IPF patients. [7]
Due to these negative studies, interferon-gamma-1b
received the “strong no” recommendation, based on high
quality evidence, with a high value placed on treatment
cost and potential risks. [4]
We should now discuss those pharmacological agents
that received a “weak no” recommendation. N-acetylcys-
teine (NAC) monotherapy received this recommendation,
placing high value on the reduction of treatment-related
morbidity and a low value on low quality data. [4] The
Idiopathic Pulmonary Fibrosis International Group
Exploring N-Acetylcysteine I Annual (IFIGENIA) [8]
study investigated triple combination therapy with high-
dose NAC (600 mg TID) versus placebo on a “standard”
background therapy of prednisone and azathioprine in all
IPF patients enrolled. The primary endpoint of the study
was change in vital capacity (VC) and diffusing capacity
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(DLco), and NAC was found to significantly reduce
decline in VC and DLco after one year. However, there
were numerous limitations to interpreting these data, such
as not all patients being included in the intention-to-treat
(ITT) analysis, which violated the ITT population para-
digm and the omission of a “placebo-only” treatment arm
to allow direct comparison versus a negative control. In
addition, use of the last observation carried forward
(LOCF) method of analysis, which inflates Type I errors
and may overestimate treatment effect, and the fact that it
was not clear how important the observed effect was with
regard to patient relevant outcomes like quality of life, dys-
pnea, and survival. It is as a consequence of these limita-
tions that the evidence level is considered low quality. In
addition, the recent publication of the full results of the
Prednisone, Azathioprine, and N-Acetylcysteine: A Study
That Evaluates Response in Idiopathic Pulmonary Fibrosis
(PANTHER-IPF) study demonstrated that there was an
increased risk of death and hospitalizations in patients
with IPF treated with a combination of prednisone,
azathioprine, and NAC, as compared with placebo. [9]
However, desite the suggestion from these conflicting data
and recommendations that high dose steroid therapy and
azathioprine should not be used in IPF, combined NAC
with immunosuppression together has been widely used
as a conventional approach to the treatment of IPF. Thus,
the recommendation for NAC combination treatment has
been heavily debated, but is generally perceived to be an
appropriate treatment for patients who are willing to
accept possible adverse consequences, even if the expected
benefits are small, i.e. a “weak no” recommendation.
Although the use of anti-oxidant monotherapy is not
necessarily clear from PANTHER, the NAC-monotherapy
and placebo arms of the PANTHER-IPF study are
continuing.
Anticoagulant therapy also received a “weak no” recom-
mendation from the ATS/ERS/JRS/ALAT committee. Use
of anticoagulants has been investigated in a small,
unblinded, randomised study in Japan. [10] Anticoagula-
tion plus corticosteroids or corticosteroids alone was
administered to patients. A survival benefit was demon-
strated in patients treated with anticoagulation therapy,
and thought to be due to reduced mortality during hospi-
talisation for acute exacerbation or respiratory worsening.
However, there were significant limitations to this study
including the absence of blinding, imbalanced dropout
rates, failure to exclude pulmonary embolism as the cause
of deterioration and insufficient documentation regarding
anticoagulant administration during outpatient treatment.
In addition, the ACE-IPF study of coumadin in IPF ended
in 2011 due to ineffectiveness and was also associated with
an increased risk of mortality in an IPF population who
lacked other indications for anticoagulation. [11] This sug-
gests that there is no role for warfarin-type anticoagulants
in the treatment of IPF. These data do not exclude, how-
ever, that anticoagulant therapy with unfractioned heparin
or low-molecular-weight heparin may have beneficial
effects in patients with acute exacerbation of IPF, which
should be investigated further. [11]
The final agent that received a “weak no” recommenda-
tion that was discussed is pirfenidone. Four randomised,
placebo-controlled clinical trials have evaluated the treat-
ment of IPF patients with pirfenidone to date. The Phase II
study by Azuma et al., was stopped early due to the inci-
dence of acute exacerbations in patients treated with pla-
cebo, while none occurred with pirfenidone treatment. [12]
A Japanese Phase III study demonstrated a significant effect
on decline of FVC and on progression-free survival in
patients treated with pirfenidone, compared with placebo.
A limitation of this study was that the primary endpoint
was changed before unblinding. [13] The multinational
CAPACITY studies investigated pirfenidone treatment in
IPF patients. The CAPACITY 004 study demonstrated a
significantly reduced decline in % predicted FVC compared
with placebo. However, the primary endpoint was not met
in the CAPACITY 006 study, but pooled data from both
studies support the treatment effect of pirfenidone. [14]
The guideline committee gave a ‘weak no’ recommenda-
tion, with high value placed on costs and side effects and
low value on the possible small reduction in pulmonary
decline. Again, this treatment may be appropriate in
patients who are willing to accept possible adverse effects
even if the benefits are small. [4] The majority of commit-
tee member abstained (16/31) from voting on pirfenidone,
because most were involved in the CAPACITY Trials. In
addition, the guidelines were devised before the CAPA-
CITY study data had been published, and without taking
into consideration the positive findings of the Cochrane
meta-analysis of pirfenidone data. [15] While the FDA
refused approval of pirfenidone based on the two CAPA-
CITY Studies, the European Medicines Agency (EMA)
approved pirfenidone in Europe in 2011, based on all of
the available data, including the Japanese studies and the
Cochrane meta-analysis. The discrepancies between the
decisions of the FDA, the EMA and the guideline commit-
tee demonstrate that there are different ways to interpret
these clinical trials. As the quality of evidence at the time
of writing the guidelines was considered “low-to-moder-
ate”, this suggests that the complete dataset available to
date is likely to have an important impact on the commit-
tee’s confidence in the treatment effect of pirfenidone, and
this may change their recommendation at some point.
In terms of non-pharmacological treatment, treatment
options receiving “strong yes” recommendations were
long-term oxygen treatment and lung transplantation.
“Weak yes” recommendations were given for pulmonary
rehabilitation, corticosteroids in acute exacerbations and
for treatments of asymptomatic gastrointestinal reflux
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disease. There were “weak no” recommendations for
specific treatment of pulmonary hypertension in the IPF
setting and for mechanical ventilation for respiratory
failure due to IPF. [4]
Conclusions
As discussed, no single pharmacological agent was recom-
mended for use in the treatment of patients with IPF.
Currently, the only approved treatment option that we
have in Europe is pirfenidone. We, as physicians, must dis-
cuss the available options with individual patients and
then make a treatment decision with the patient based on
their specific values and preferences. As we know, fully
informed patients are best placed to make decisions that
are consistent with the best available evidence. Since fina-
lising the 2011 IPF guideline document at the end of the
year 2010, more data has become available regarding the
efficacy and safety of pirfenidone, and also in terms of the
safety of immunosuppression-based triple therapy. In
addition, some studies have failed with other putative
agents, and it is possible to make recommendations on
some agents that were considered ‘investigative’ in the
2011 document but have now proven to be ineffective and
are no longer an option. Although the 2011 document is
useful in many aspects, we feel that an update of the
guidelines is essential, as new information from the mole-
cular level to clinical trials have already provided useful
information that can help in determining the best way to
treat our patients with IPF.
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